Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jun 1;152(6):698-701.
doi: 10.1001/jamadermatol.2016.0225.

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

Carole Bitar  1 , Mohammed Z H Farooqui  2 , Janet Valdez  2 , Nakhle S Saba  3 , Susan Soto  2 , Amanda Bray  2 , Gerald Marti  2 , Adrian Wiestner  2 , Edward W Cowen  4
Affiliations
Clinical Trial

Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia

Carole Bitar et al. JAMA Dermatol. .

Abstract

Importance: Ibrutinib, a Bruton tyrosine kinase inhibitor, is a new targeted agent approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia. Ibrutinib is overall well tolerated but long-term treatment is required until disease progression or intolerable toxic effects occur. Little is known regarding its cutaneous adverse effects.

Objective: To describe the hair and nail manifestations associated with the long-term use of ibrutinib for the treatment of CLL.

Design, setting, and participants: Prospective study of 66 patients with CLL enrolled in a single-arm phase 2 clinical trial of ibrutinib for CLL between March 2014 and October 2015 at the National Institutes of Health.

Main outcomes and measures: The primary outcome, nail and hair changes associated with ibrutinib therapy, was assessed by an 11-question survey. In addition, the severity of nail changes was determined from a 0 to 3 rating scale for both onychoschizia and onychorrhexis.

Results: Among 66 patients (43 men and 23 women with ages ranging from 55 to 85 years), 44 (67%) reported brittle fingernails at a median of 6.5 (95% CI, 6-12) months after starting ibrutinib therapy. Fifteen patients (23%) developed brittle toenails after a median of 9 (95% CI, 6-15) months of ibrutinib therapy. Textural hair changes were reported in 17 patients (26%), at a median of 9 (95% CI, 6-12) months of ibrutinib treatment.

Conclusions and relevance: Hair and nail abnormalities are commonly associated with ibrutinib and appear several months after initiating therapy. Ibrutinib inhibits Bruton tyrosine kinase by covalently binding to cysteine 481. Whether ibrutinib affects the hair and nails by binding and altering cysteine-rich proteins of hair and nails or by means of another mechanism remains unknown.

Trial registration: clinicaltrials.gov Identifier: NCT01500733.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure:

Dr. Wiestner received research funding from Pharmacyclics. Dr. Saba serves as consultant and a speaker for Pharmacyclics. All other authors declare no competing interests.

Figures

Figure 1.
Figure 1.. Ibrutinib-associated onychorrhexis of the fingernails.
Moderate onychorrhexis of the fingernails in a CLL patient after 6 months of ibrutinib therapy.
Figure 2:
Figure 2:. Ibrutinib-associated onychoschizia of the toenails.
Onychoschizia of the toenails 11 months after starting ibrutinib.
See this image and copyright information in PMC

References

    1. Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 2015;100(12):1495–1507. - PMC - PubMed
    1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369(1):32–42. - PMC - PubMed
    1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369(6):507–516. - PMC - PubMed
    1. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med 2015;372(15):1430–1440. - PubMed
    1. Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014;123(21):3286–3295. - PMC - PubMed

Publication types

MeSH terms

Associated data